Mobile

Study of efficacy and safety of QVA149 compared to standard of care, a combination of fluticasone/salmeterol, in patients with moderate to severe COPD

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005102-22

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the superiority of QVA149 27.5/12.5 μg twice a day as compared to fluticasone/salmeterol 250/50 μg twice a day in COPD patients with moderate to severe airflow limitation in terms of standardized FEV1 AUC0-12h at Week 12.

Critère d'inclusion

  • COPD patients with moderate to severe airflow limitation

Liens